当前位置: X-MOL 学术Eur. J. Nucl. Med. Mol. Imaging › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
In vivo characterization of [18F]AVT-011 as a radiotracer for PET imaging of multidrug resistance.
European Journal of Nuclear Medicine and Molecular Imaging ( IF 8.6 ) Pub Date : 2019-11-15 , DOI: 10.1007/s00259-019-04589-w
Pavitra Kannan 1, 2 , András Füredi 3, 4 , Sabina Dizdarevic 5 , Thomas Wanek 6 , Severin Mairinger 6 , Jeffrey Collins 7 , Theresa Falls 7 , R Michael van Dam 7, 8 , Divya Maheshwari 9 , Jason T Lee 7, 8, 10 , Gergely Szakács 3, 4 , Oliver Langer 6, 11, 12
Affiliation  

Multidrug resistance (MDR) impedes cancer treatment. Two efflux transporters from the ATP-binding cassette (ABC) family, ABCB1 and ABCG2, may contribute to MDR by restricting the entry of therapeutic drugs into tumor cells. Although a higher expression of these transporters has been correlated with an unfavorable response to chemotherapy, transporter expression does not necessarily correlate with function. In this study, we characterized the pharmacological properties of [18F]AVT-011, a new PET radiotracer for imaging transporter-mediated MDR in tumors.

中文翻译:

[18F]AVT-011 作为多药耐药性 PET 成像的放射性示踪剂的体内表征。

多药耐药性 (MDR) 阻碍了癌症治疗。来自 ATP 结合盒 (ABC) 家族的两种外排转运蛋白 ABCB1 和 ABCG2 可能通过限制治疗药物进入肿瘤细胞而促成 MDR。尽管这些转运蛋白的较高表达与对化疗的不利反应相关,但转运蛋白的表达不一定与功能相关。在这项研究中,我们描述了 [ 18 F]AVT-011的药理学特性,这是一种新的 PET 放射性示踪剂,用于对肿瘤中转运蛋白介导的 MDR 进行成像。
更新日期:2019-11-15
down
wechat
bug